Literature DB >> 11592364

Presence of a population of CD20+, CD38- B lymphocytes with defective proliferative responsiveness in the synovial compartment of patients with rheumatoid arthritis.

C C Reparon-Schuijt1, W J van Esch, C van Kooten, N P Ezendam, E W Levarht, F C Breedveld, C L Verweij.   

Abstract

OBJECTIVE: To provide a comprehensive understanding of the humoral immune response that takes place at the site of inflammation in rheumatoid arthritis (RA), we studied the functional properties of synovial B cells. In particular, the response to various modes of mitogen stimulation was investigated.
METHODS: Purified synovial fluid (SF) B cells were cultured in the presence of CD40 ligand (CD40L)-expressing fibroblasts and cytokines, activated T cells, or phorbol myristate acetate (PMA)/ionomycin. Proliferation was determined by 3H-thymidine incorporation. Release of intracellular calcium was studied by flow cytometry.
RESULTS: The inflamed joints of RA patients contained a population of CD20+,CD38- B cells with dramatically impaired mitogen responsiveness. Although the Ig-producing capacity was intact, these cells failed to proliferate in response to (a) CD40 in the presence of interleukin-2 (IL-2) and IL-10, (b) activated T cells, or (c) stimulation via the B cell receptor. Moreover, SF CD20+,CD38- B cells revealed a defective B cell receptor-induced Ca2+ influx, reminiscent of anergic B cells. Release of intracellular Ca2+ by ionomycin in the presence of the protein kinase C activator PMA did not restore the proliferative capacity. These findings indicate blockades in the proximal and distal intermediates involved in mitogen signaling.
CONCLUSION: SF CD20+,CD38- B cells have functionally impaired proliferative responsiveness. The capacity of these cells to respond to activation by the production of Ig supports the notion that these cells might serve as Ig-producing effector cells and, as such, play a role in the pathophysiology of RA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592364     DOI: 10.1002/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

Review 1.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

2.  The impact of Rituximab therapy on the chromosomes of patients with Rheumatoid arthritis.

Authors:  Sekib Sokolović; Sida Kasumagić; Mirela Mackić-Durović; Izeta Aganović-Musinović
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

Review 3.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 4.  Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases.

Authors:  P Stolt; C Bengtsson; B Nordmark; S Lindblad; I Lundberg; L Klareskog; L Alfredsson
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

5.  B lymphocyte-typing for prediction of clinical response to rituximab.

Authors:  Hans-Peter Brezinschek; Franz Rainer; Kerstin Brickmann; Winfried B Graninger
Journal:  Arthritis Res Ther       Date:  2012-07-06       Impact factor: 5.156

6.  Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody.

Authors:  Anne-Sophie Rouzière; Christian Kneitz; Arumugam Palanichamy; Thomas Dörner; Hans-Peter Tony
Journal:  Arthritis Res Ther       Date:  2005-04-01       Impact factor: 5.156

Review 7.  Autoantibodies to posttranslational modifications in rheumatoid arthritis.

Authors:  Agata N Burska; Laura Hunt; Marjorie Boissinot; Rocky Strollo; Brent J Ryan; Ed Vital; Ahuva Nissim; Paul G Winyard; Paul Emery; Frederique Ponchel
Journal:  Mediators Inflamm       Date:  2014-03-23       Impact factor: 4.711

8.  Rituximab therapy in Greek patients with rheumatoid arthritis.

Authors:  Aristotelis P Tsiakalos; Nestor K Avgoustidis; Haralampos M Moutsopoulos
Journal:  Biologics       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.